

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ryozo NAGAI et al.

Group Art Unit: not assigned

Serial No. : 10/565,997
(National Stage of PCT/JP2004/11223)

Examiner: not assigned

I.A. Filed : July 29, 2004

Confirmation No.: 9551

For : RNA CAPABLE OF SUPPRESSING EXPRESSION OF
KLF5 GENE

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, Applicants hereby bring the following information to the attention of the Examiner, which includes information cited in the International Search Report of International Application No. PCT/JP04/011223, filed July 29, 2004, of which the above-referenced application is a National Stage Application.

Applicants note that the International Search Report, in English and Japanese, was provided with the application at the time of filing. An additional copy of the Search Report, in English, is provided herewith for the Examiner's convenience. The following documents are cited in the Search Report, and the Examiner is invited to review the Search Report to ascertain the relevance attributed to the documents during international examination.


1. Conkright M.D. et al., "A gene encoding an intestinal-enriched member of the Kruppel-like factor family expressed in intestinal epithelial cells", Nucleic Acids Research, Vol. 27, No. 5, pp. 1263-1270, 1999
2. Paul C.P. et al., "Effective expression of small interfering RNA in human cells" Nature Biotechnology, Vol. 20, No. 5, pp. 505-508, 2002
3. Hiroyuki OSHIUMI et al., "RNA interference (RNAi) o Mochiita Honyurui Dobutsu deno Idenshi Knockout", Folia Pharmacologica Japonica, Vol. 120, pp. 91-95, 2002, including English language abstract (on page 95)
4. Shindo, T. et al., "Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling", Nature Medicine, Vol. 8, No. 8, pp. 856-863, 2002

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

This Information Disclosure Statement is being filed prior to mailing of a first Office Action on the merits. Accordingly, no fees are required. However, if any fee is necessary for consideration of this disclosure statement, this is a request to charge any necessary fee to Deposit Account No. 19-0089.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Ryozo NAGAI et al.


Bruce H. Bernstein
Reg. No. 29,027 42,920

August 11, 2006
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

{P29215 00045711.DOC}